Free tool
Medicare drug spending
Last checked: Nov 20, 2026Latest source record: 2024 calendar yearSource: CMS (Medicare Part D Spending by Drug : 2024-01-01; Medicare Part B Spending by Drug : 2024-01-01)Methods & limitations
Part D, 2024
$288.7B
Gross drug spending in the dataset
Part B, 2024
$60.8B
Gross drug spending in the dataset
Drugs listed
3
Part D and Part B
Total spending by year
- Part D
- Part B
View as table
| Year | Part D | Part B |
|---|---|---|
| 2020 | $194,092,038,339 | $37,778,829,680 |
| 2021 | $213,513,349,361 | $40,135,340,775 |
| 2022 | $239,779,215,689 | $44,241,259,745 |
| 2023 | $275,808,918,753 | $50,775,853,083 |
| 2024 | $288,667,842,058 | $60,838,164,403 |
Top 3 by total spending
2024 figures. Growth compares with 2023. Per-beneficiary ranks skip drugs with fewer than 11 beneficiaries.
| Drug | Part | Spending | Change | Beneficiaries | Per beneficiary | Per unit |
|---|---|---|---|---|---|---|
| Caspofungin Acetate Caspofungin Acetate | D | $1.4M | -24% | 1,263 | $1,099 | $12.81 |
| Cancidas Caspofungin Acetate | D | $24K | -57% | n/a | n/a | $114.67 |
| Cancidas* Caspofungin Acetate* · J0637 | B | $15K | -67% | 21 | $710 | $6.34 |
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.